Figure 6
The influence of doxorubicin and/or HSV1-hGM-CSF on ALDH br tumor cells in vivo . (A) An aldefluor assay of ALDHbr in in vivo-treated primary tumors as described in the Methods section. Representative images of flow cytometry from the four groups are depicted. The upper panels are the gates to exclude APC anti-mouse CD45+ leukocytes. The percent of CD45- cells was as followed: 33.45% for DOX+OV, 58.89% for DOX, 56.54% for OV and 61.69% for Control. (B) The mean frequency of ALDHbr tumor cells in the four groups are as follows (n=4-5). The experiment was performed twice with similar findings. (C) The influence of the primary tumor volume on 4T1 ALDHbr cells in vivo. The mean tumor volume (left), and the mean percentage of ALDHbr tumor cells (right, n=3-5) both increased with time. The data represent the mean ± SEM in triplicate. *, p < 0.05; ***, p < 0.001. Abbreviations: DOX, doxorubicin; OV, HSV1-hGM-CSF.